Bhaskar Tare, Director of Gloocal Communications, honoured with Pride of Spandan Award 2024

 

Bhaskar Tare, Director of Gloocal Communications, was honored with the prestigious "Pride of Spandan Award 2024" in recognition of his remarkable two-decade journey in the field of public relations. Known for his expertise in reputation management, Mr. Tare has also been a beacon of hope for countless needy patients, providing them with guidance, direction, and financial assistance through available CSR resources. The state-level ceremony took place in Karad, a city celebrated as the birthplace of Maharashtra's first Chief Minister, Yashwantrao Chavan.

The award was presented to Mr. Tare by Dr. Nilkanth Dharsewar Maharaj and Mr. Mangesh Chivate, former head of the Chief Minister's Relief Fund. The ceremony was graced by eminent dignitaries, including Dr. Sandip Dakve, President of Spandan Charitable Trust; journalists Bhimrao Dhulap and Gajanan Tupe; and renowned singer Kavita Ram.

A trailblazer in the field of public relations, Bhaskar Tare embarked on his professional journey in 2005. Over the past two decades, he has built a formidable reputation as an expert in reputation management. Under his leadership, Gloocal Communications has successfully managed the public image of numerous prominent hospitals and companies, offering a range of PR and digital marketing services across India.

Beyond his professional accomplishments, Mr. Tare has exemplified a strong commitment to social responsibility. Through Gloocal Communications and personal initiatives, he has supported countless patients in need, creating a lasting positive impact. His efforts have also provided employment opportunities to over 25 young professionals, fostering their growth and development in the industry.

Upon receiving the award, Mr. Bhaskar Tare expressed his gratitude and humility, stating "I am deeply honored to receive the Pride of Spandan Award 2024. This recognition motivates me to continue striving to make a positive difference in the lives of others. I extend my heartfelt thanks to Dr. Sandip Dakve and the Spandan Charitable Trust for this esteemed acknowledgment."

The Pride of Spandan Award celebrates individuals who have made exemplary contributions to their fields and society. Bhaskar Tare's dedication to excellence and his unwavering commitment to giving back to the community truly embody the spirit of this honor.

Dr. Chandrakant Agarwal envisions a Thalassemia-Free India

 

By persevering in the face of challenges and persisting with his vision, Dr. Chandrakant Agarwal is leading the charge to make thalassemia a thing of the past in India. His work reminds us that with collective will and determined action, even the most daunting challenges can be overcome.

Dr. Chandrakant Agarwal, the President of the Thalassemia and Sickle Cell Society (TSCS) in Hyderabad, states that Thalassemia disorder represents not just a medical challenge but a call to action. His relentless efforts are driving a nationwide movement to create a “Thalassemia Mukt Bharat.”

Early Detection: The Key to Prevention

For Dr. Agarwal, prevention is the cornerstone of his mission. He emphasizes the importance of early detection through simple yet critical blood tests like the HbA2 test during the first trimester of pregnancy. "Due to a lack of awareness, even some doctors fail to recommend the HbA2 test to pregnant women," he notes. "Screening is essential to prevent the transmission of thalassemia to unborn children."

Under his leadership, Mahbubnagar district in Telangana became the first in India to achieve 100% prenatal screening for thalassemia, setting a benchmark for other regions. This achievement underscores the power of community engagement and government collaboration in combating hereditary disorders.

Thalassemia, a hereditary blood disorder, poses significant health challenges due to the body's inability to produce sufficient hemoglobin—the oxygen-carrying protein in red blood cells. While the condition varies in severity, the most severe forms can lead to lifelong dependence on blood transfusions and other intensive treatments. For

The Challenge of Thalassemia

Thalassemia comes in two main forms: alpha and beta thalassemia. While alpha thalassemia affects the alpha-globin genes, beta thalassemia impacts the beta-globin genes. The most severe forms, such as alpha thalassemia major and beta thalassemia major (Cooley’s anemia), result in life-threatening complications that require regular blood transfusions and iron chelation therapy. Symptoms like fatigue, slow growth, bone deformities, and organ enlargement make this condition a significant burden for patients and their families.

A Comprehensive Approach to Care

Dr. Agarwal’s vision extends beyond prevention to the holistic care of those already affected by thalassemia. At the TSCS center in Hyderabad, over 4,000 children receive free medical care each month. Services include blood transfusions, iron chelation therapy, and advanced diagnostic tests. Additionally, the center provides free food and psychological counseling for patients and their families, ensuring emotional and physical well-being.

“Treatment is only one part of the equation,” Dr. Agarwal explains. “We focus on empowering families through education and support, helping them navigate this challenging journey with dignity and hope.”

Mobilizing Government and Philanthropy

One of Dr. Agarwal’s key strategies is leveraging partnerships with government schemes like Aarogya and mobilizing philanthropic contributions. This collaborative approach has enabled TSCS to expand its reach and offer services that are entirely free of cost, making it accessible to underserved communities.

A Global Model for Change

Dr. Agarwal’s work has earned TSCS recognition as a global leader in thalassemia care. The organization’s model—integrating prevention, treatment, and community support—has attracted attention from international groups, eager to replicate its success.

A Future Without Thalassemia

Dr. Agarwal’s ultimate goal is clear: to eliminate thalassemia from India entirely. Achieving this requires mandatory HbA2 testing for all pregnant women, widespread public awareness, and sustained government support. As he tirelessly campaigns for a thalassemia-free future, Dr. Agarwal’s leadership and dedication inspire hope, transforming the lives of thousands and setting a powerful example for the world.

AIPAC kicks off landmark Pharma MSME programme in Indore with overwhelming response

 Shardul Nautiyal, Mumbai

The All India Pharmaceutical Associations Consortium (AIPAC) recently unveiled its maiden initiative for Micro, Small, and Medium Enterprises (MSMEs) in the pharmaceutical sector at the Prestige Institute of Management and Research, Indore. The event, with over 250 delegates in attendance, marked a pivotal moment in the empowerment of MSMEs through skill development and scientific excellence.

Dr. Rajeev Singh Raghuvanshi, Drugs Controller General of India (DCGI) inaugurated the event, setting the tone for a transformative day. Themed “Symposium on Dissolution Science and Technology for QA, QC, R&D, and Regulatory Professionals of Pharma”, the programme focused on equipping professionals with cutting-edge knowledge and techniques in dissolution science and quality control.

AIPAC collaborated with leading industry bodies such as the Society for Pharmaceutical Dissolution Science (SPDS), Indian Drug Manufacturers’ Association (IDMA-MP), and Madhya Pradesh State Drugs and Pharmaceutical Manufacturers Association (MPSDMA) to organize this landmark event.

Key figures such as Dr. L. Ramaswamy, Founder and National Convenor of AIPAC, and S. R. Vaidya, Chairman of IDMA’s SME Committee, Paresh Chawla, Chairman, MP Branch of IDMA, played crucial roles in the programme's success. Esteemed speakers, including industry veterans like Vijay Kshirsagar, Suhas Yewale, Dr. Padma Devarajan, and others, delivered insightful sessions on topics ranging from regulatory compliance to advancements in dissolution methods.

Dr. Raghuvanshi, in his keynote address, emphasized the importance of raising industry standards and fostering collaboration between MSMEs, regulators, and academia. "Empowering MSMEs is not just about growth; it's about ensuring the production of quality, affordable medicines for millions," he remarked.

The event also highlighted AIPAC's mission to provide affordable and specialized training to MSMEs. By bridging the gap between MSMEs and regulatory bodies like CDSCO and Indian Pharmacopoeia, AIPAC aims to enhance compliance and quality in pharmaceutical manufacturing.

MPSDMA President Dr. Darshan Kataria announced the association’s integration into AIPAC, signalling a growing coalition dedicated to addressing the unique challenges faced by MSMEs. Global dissolution testing leader SOTAX and other prominent organizations such as USP, IP, and Asian Paints supported the initiative, significantly subsidizing delegate fees.

Based on the overwhelmingly positive feedback from delegates, AIPAC has already scheduled its next events in February 2025—one in Chandigarh in collaboration with National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, and another in Bangalore with Federation of Pharma Entrepreneurs (FOPE). The consortium also committed to conducting quarterly programmes nationwide, focusing on diverse topics to enhance quality systems and production.

AIPAC's inaugural programme not only underscored the sector's potential but also demonstrated the power of collaboration between regulators, industry leaders, and academia. As India’s pharmaceutical sector continues to grow, initiatives like these are poised to play a crucial role in ensuring quality, compliance, and innovation across the industry.

(Source - Pharmabiz)

Methylcobalamin a game-changer in clinical practice & modern medicine: Dr Sanjay Agrawal

 

By Shardul Nautiyal 

In a comprehensive review of its therapeutic potential, Dr Sanjay Agrawal, Scientific Advisor of Alkomex GBN USA, highlights the pivotal role of methylcobalamin in modern clinical practice.

Dr Agrawal urges greater awareness among healthcare professionals about the benefits of methylcobalamin. “Its role in treating conditions like diabetic neuropathy, chronic pain, and neurological disorders underscores its importance as a cornerstone of modern medicine.”

Vitamin B12, a crucial water-soluble vitamin, is integral to DNA synthesis, red blood cell production, and neurological function. It is predominantly found in animal-based foods like meat, fish, and dairy products, with plant-based foods providing little to none. Deficiency in this vitamin can lead to serious health consequences, often requiring supplementation.

“Methylcobalamin, an active form of vitamin B12, is the most bioavailable and therapeutically effective form. Unlike cyanocobalamin, which requires biotransformation, methylcobalamin is readily absorbed and utilized by the body, making it a preferred choice for supplementation,” says Dr Agrawal.

Methylcobalamin has been extensively studied and used in clinical practice since the 1990s. According to Dr Agrawal, its benefits extend far beyond basic vitamin B12 supplementation.

“Laboratory and clinical evidence demonstrate its effectiveness in promoting healthy nerve function, relieving neuropathic pain, and reducing inflammation,” Dr Agrawal explains.

Its key benefits include promoting myelin synthesis and nerve regeneration, providing analgesic effects for nerve-related pain, offering antioxidant and anti-inflammatory properties.

Dr Agrawal notes that methylcobalamin has shown remarkable efficacy in managing neurological disorders, including diabetic peripheral neuropathy (DPN). Clinical trials have demonstrated significant reductions in pain and disability scores among patients treated with methylcobalamin.

Chronic low back pain and neck pain - Randomized studies reveal improved pain scores and functionality with methylcobalamin injections compared to placebos.

Patients reported dramatic pain relief, with some experiencing a 50% reduction in pain through daily methylcobalamin injections in trigeminal neuralgia and herpetic neuralgia.

Faster recovery of facial nerve function has been observed with methylcobalamin therapy in Bell’s palsy cases. Studies indicate improvements in communication, oxidative stress, and survival rates in early-treated autism and ALS (amyotrophic lateral sclerosis) patients.

Dr Agrawal emphasizes the safety profile of methylcobalamin, which is well-tolerated even at high doses. “Clinical studies using doses up to 50 mg twice weekly have reported no significant side effects,” he says.

Research also supports methylcobalamin’s ability to cross the blood-brain barrier, unlike other forms of vitamin B12. “This unique property allows it to directly impact neurotransmitter activity and protect the brain,” adds Dr Agrawal.

“Methylcobalamin can be administered orally, intramuscularly, or intravenously, with therapeutic doses ranging from 1,500 to 6,000 µg per day. Lower doses, administered over extended periods, have also proven effective,” Dr Agrawal advises.

“Methylcobalamin addresses fundamental issues in neuropathic pain and nerve damage. Its ability to reduce inflammation, promote nerve regeneration, and provide analgesic effects makes it an invaluable tool in clinical practice,” says Dr Agrawal.

(Source- www.pharmabiz.com)

 

 

FPME Annual Conclave - 2024 deliberates global supply chain resilience and quality excellence through collaborations

 

The pharmaceutical export community gathered in Mumbai for the highly anticipated event, "Know Your Value," centred on the critical roles of the Government, Directorate General of Foreign Trade (DGFT), Central Drugs Standard Control Organization (CDSCO), and Customs in facilitating pharmaceutical exports across resilient global supply chains. The event, organized by the Federation of Pharmaceutical and Allied Products Merchant Exporters (FPME), featured a robust agenda, a CEO panel discussion, and an awards ceremony. It also included a Motivational Session by Arun Sehgal, managing director, Chempro Group.

President of FPME and Director of MT Madon Exports Pvt Ltd Kamlesh Shah was also felicitated for completing 50 years in pharma exports business.

Dr Vinay Sahasrabuddhe, former Rajya Sabha MP and vice-chairman of Rambhau Mhalgi Prabodhini, delivered the keynote address, emphasizing the need for streamlined regulatory processes to bolster pharma exports. Paresh Mehta, regional chairman (WR) of the Federation of Indian Export Organizations (FIEO), highlighted the significant contributions of merchant exporters to India's economy.

“The DGFT has been playing a pivotal role in enhancing India's trade capabilities through targeted schemes like the Advance Authorisation Scheme (AAS), the Export Promotion Capital Goods (EPCG) Scheme, the Remission of Duties and Taxes on Exported Products (RoDTEP) refund duties incurred during manufacturing, such as electricity or embedded taxes. This ensures that Indian products are priced competitively in global markets”, stated deputy DGFT Vishwajeet G Chimankar.

The event included an in-depth discussion on government schemes, with inputs from Jayant Kumar, Deputy Drugs Controller (West Zone 2), CDSCO), and Kaushal Thakker, managing director of Harish & Company Pvt. Ltd. Topics included regulatory compliance and logistics optimization for pharma exports.

The CEO roundtable addressed crucial themes such as manufacturing challenges, global logistics, regulatory compliance, and the future prospects of the pharmaceutical industry. Panelists included Harish Jain, director, Embiotic Laboratories Pvt. Ltd, Dr. Ramaswamy Lakshmanan, chairman, Sotax India Pvt. Ltd, Ramesh Rughani, chairman & MD, Khyati Global Ventures Ltd, Ashish Vora, founder & chairman, Prime Pharma Pvt. Ltd.

Dr. Ramaswamy Lakshmanan remarked, "The resilience of India's pharmaceutical export supply chain lies in the collaboration of stakeholders, from regulators to exporters. Initiatives like this not only elevate standards but also inspire collective action towards global healthcare objectives."

FPME highlighted its commitment to supporting over 500 SME pharma companies involved in exports, seeking certifications in collaboration with the stakeholders.

 FPME's leadership, including Sandeep Modi and Dharmesh Kharwar, joint secretary, conducted the proceedings. In his vote of thanks, Kharwar expressed gratitude to all participants, stating, "The success of this event is a testament to our collective vision for advancing India's position as a global pharmaceutical leader."

FPME expressed optimism about working closely with regulatory bodies like DGFT, CDSCO, and Customs. These partnerships aim to ensure rigorous auditing, post-audit inspections, and targeted training to enhance product quality and supply chain resilience. The event served as a milestone in fostering collaboration across stakeholders, reflecting India’s growing influence in the global pharmaceutical landscape.

 

GBMA recommends rodent control as key GMP strategy for pharma industry amid imminent leptospirosis and plague threats

Shardul Nautiyal, Mumbai

The Glue Board Manufacturers Association (GBMA) has recommended that the pharmaceutical industry adopt rodent control as a critical part of Good Manufacturing Practices (GMP) to meet global and domestic regulatory requirements. With an imminent surge in leptospirosis and plague cases, effective rodent control is becoming essential for public health and safety.

GBMA also warned that recent advisories from the Animal Welfare Board of India (AWBI), which could lead to restrictions on glue boards, may jeopardize public safety and disrupt industries reliant on these tools. The association called for regulatory clarity, highlighting that banning glue boards without viable alternatives could severely impact health standards, compromising both industry operations and national well-being.

Meanwhile, the pharmaceutical industry is taking proactive steps to integrate rodent control into GMP with a rising concern over the spread of rodent-borne diseases such as leptospirosis and plague. The recent surge in these diseases, both of which are transmitted by rodents, has heightened the urgency for stringent pest control measures, particularly in facilities responsible for public health and safety.

At the forefront of this initiative is the GBMA, which has long advocated for the use of glue boards as a crucial and affordable tool in maintaining rodent control. GBMA underscored that glue boards are vital in preventing the spread of these life-threatening diseases, especially in industries like pharmaceuticals, where maintaining strict hygiene is paramount.

Mukesh Patel, secretary of GBMA and managing director of Arbuda Agrochemicals, stated, “Rodents pose a significant health risk by transmitting diseases such as leptospirosis and plague. The use of glue boards in rodent control is not just a matter of industry preference, but a necessity for protecting public health. Disrupting access to such critical tools without viable alternatives will only worsen the situation.”

The pharmaceutical sector, which relies on stringent sanitary conditions, has been adopting more rigorous pest control protocols, incorporating glue boards and other rodent control methods as part of their GMP strategies. The aim is to prevent contamination of pharmaceutical products and safeguard the health of workers and consumers alike. Given the rise of rodent-borne diseases, pharma companies are looking to glue boards as part of their integrated pest management solutions, ensuring that their facilities remain rodent-free.

However, recent circulars from the AWBI have raised concerns about the future of glue boards, citing animal welfare considerations. Although no formal ban has been issued, confusion over regulatory advisories has led to misinformation, causing disruptions in industries that rely on these tools. GBMA stressed that comprehensive studies are needed to evaluate alternatives to glue boards and to ensure that public health concerns are weighed against animal welfare issues in a balanced regulatory framework.

Despite the regulatory uncertainty, GBMA has reaffirmed its commitment to ensuring the responsible use of glue boards, advocating for proper handling and disposal practices to mitigate any unintended harm to non-target species. As leptospirosis and plague cases continue to threaten public health, the pharma industry is rallying behind the need for effective rodent control measures, with glue boards playing a central role in maintaining safety standards.

As part of its broader effort, GBMA has launched a public awareness campaign to educate industries and pest control operators on the ethical use of glue boards. The association continues to appeal for regulatory clarity and engagement with stakeholders to ensure that effective rodent control methods remain accessible.

In conclusion, with the looming threat of disease outbreaks, the pharmaceutical industry is emphasizing the importance of rodent control as a critical component of their operational safety. The adoption of glue boards, amidst calls for regulatory reassessment, highlights the ongoing battle to safeguard public health against preventable diseases.

 https://www.pharmabiz.com/NewsDetails.aspx?aid=166312&sid=1

DGTR issues revised list of 18 parties issued in ECH anti-dumping probe

Shardul Nautiyal, Mumbai Tuesday, February 13, 2024, 08:00 Hrs  [IST]

The Directorate General of Trade Remedies (DGTR) has released a revised list of interested parties in the ongoing anti-dumping inquiry concerning epichlorohydrin (ECH) imports from Korea, Thailand and China. This is aimed at fostering transparency and inclusivity in the investigation process. The DGTR had extended the timeline up to November 30, 2023 for filing responses in the anti-dumping investigation. The DGTR's decision to revise the list comes following feedback received on the previously published notice dated November 3, 2023. ECH is used in pharmaceutical API and can be produced using propylene as well as using glycerine. Meghmani Finechem Limited had filed an application before the DGTR for initiation of an anti-dumping investigation concerning imports of ECH from Korea, Thailand and China. The applicant has alleged that dumping of imports of the subject goods originating in or exported from the subject countries has materially retarded the establishment of the domestic industry and has caused material injury to the domestic industry. The updated list encompasses a diverse range of entities representing various segments of the industry involved in the production, export, import, and utilization of epichlorohydrin. From domestic industries to government bodies, producers, exporters, importers, and users, the revised list seeks to provide a comprehensive representation of interests affected by the anti-dumping measures. Among the prominent parties listed are Meghmani Finechem Limited, which represents the domestic industry's interests, Royal Thai Government, which advocates for Thailand's trade concerns, AGC Vinythai Public Co. Ltd, producer or exporter from Thailand, importers or users like Cardolite Speciality Chemicals India LLP, Atul Limited, Hindustan Speciality Chemicals Limited, Grasim Industries Ltd, Hanwha Solutions Corporation, producer from Korea, Canko Marketing, Inc, exporter from Korea, Everlite Korea Co. Ltd, exporter from Korea, Minjin Corporation, exporter from Korea, Lotte Fine Chemical Co. Limited, exporter from Korea, Jiangsu Ruixiang Chemical Co., Ltd, producer or exporter from China, Ningbo Huanyang New Material Co., Ltd, producer, exporter from China, China Chlor-Alkali Industry Association, producer or exporter from China, Rishabh Metals and Chemicals Pvt. Ltd, importer or consumer, Sandeep Organics Pvt. Ltd, importer and Samsung C&T (Thailand) Company Limited, exporter from Thailand. Devender Singh, joint director general (foreign trade) at DGTR, emphasized the importance of active participation and cooperation from all stakeholders in the investigation process. Singh noted that the revision aims to ensure a robust and inclusive examination of the allegations surrounding epichlorohydrin imports, ultimately leading to informed decision-making by the authorities. The anti-dumping probe into epichlorohydrin imports reflects the government's commitment to upholding fair trade practices and safeguarding the interests of domestic industries. Stakeholders are urged to comply with the prescribed guidelines and actively engage in the investigative process to facilitate a fair and equitable resolution. As the investigation progresses, stakeholders can anticipate further updates and opportunities for engagement. The outcome of the probe will have significant ramifications for trade relations and industry dynamics, underscoring the importance of collaborative efforts and adherence to regulatory procedures. In conclusion, the issuance of the revised parties list marks a pivotal step in the anti-dumping investigation, signaling the government's dedication to transparency and fairness in trade remedies.

 

Experts warn of urgent action to address confusion caused by identical drug names

Shardul Nautiyal, Mumbai Tuesday, February 13, 2024, 08:00 Hrs  [IST]

Healthcare experts in the country have raised serious concern about the widespread confusion caused by identical or similar drug names in India's healthcare system.   Urgent redressal is the need of the hour to prevent potential mishaps and ensure patient safety, according to Dr. Ishwar Gilada, a prominent infectious disease expert and secretary general of the Peoples Health Organisation-India (PHO). In addition to the alarming prevalence of identical drug names in India's healthcare system, experts are now highlighting another pressing issue, which is look-alike, sound-alike (LASA) drugs. These medications, despite having distinct purposes, share names that are phonetically and visually similar, posing significant risks to patient safety. Dr. Gilada highlighted the alarming consequences of drugs sharing identical names but serving entirely different purposes. He cited examples such as Linamac, used to treat diabetes in one form and as a treatment for multiple myeloma, a type of cancer, in another. Similarly, he underscored the dangers posed by medications like azidothiamidine, commonly known as AZT for HIV treatment, and azathioprine, also referred to as AZT, used as an immunosuppressive medication. "This issue of identical or similar drug names has long plagued the healthcare sector in India," Dr. Gilada emphasized. "While the onus lies with the Drug Controller General of India (DCGI) to select distinct names for new formulations, it requires a collective effort from all stakeholders to mitigate risks and ensure patient safety," he explained. Dr. Gilada outlined several critical measures to address this pressing issue. Firstly, he emphasized the importance of standardized prescription practices, whereby doctors clearly indicate the diagnosis along with the prescribed medication and its active ingredient. Additionally, he stressed the need for rigorous training of pharmacists to recognize and mitigate risks associated with similar-sounding drugs. "By law, chemist shops must be owned by professional pharmacists, and their staff should undergo training," Dr. Gilada asserted. "Furthermore, cross-checking prescriptions with doctors before dispensing medication is crucial to prevent errors," he added. Despite the severity of the problem, Dr. Gilada expressed concern over the lack of reported data on medication errors related to identical drug names. He urged for greater attention from the government, pharmaceutical companies, and the healthcare sector to address this critical issue and implement comprehensive solutions. Dr. Gilada further underscored the importance of heightened vigilance in the healthcare sector to prevent medication errors. "LASA drugs such as metformin for diabetes, metoprolol for heart conditions, and metronidazole for amoebiasis, often referred to as Met, Meto, and Metro respectively, demand heightened attention due to their potential for confusion," he emphasized. To address this critical issue, most hospitals maintain lists of LASA drugs to facilitate accurate prescribing and dispensing practices. However, Dr. Gilada stressed the need for broader awareness and proactive measures across the healthcare continuum. "While awareness among healthcare professionals is crucial, it is equally important for patients to be vigilant and informed about their prescribed medications," Dr. Gilada emphasized. "Collaborative efforts involving regulatory bodies, pharmaceutical companies, healthcare providers, and patients are essential to mitigate the risks associated with LASA drugs," he recommended. In conclusion, the prevalence of look-alike, sound-alike drugs pose a significant challenge to patient safety in India's healthcare system. Overall, addressing the problem of identical or similar drug names requires a multifaceted approach involving regulatory measures, improved healthcare practices, education, and collaboration across the healthcare sector.